Autism - Pipeline Review, H2 2016

Date: July 27, 2016
Pages: 134
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5CCB99A791EN
Leaflet:

Download PDF Leaflet

Autism - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Autism - Pipeline Review, H2 2016’, provides an overview of the Autism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Autism
  • The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Autism therapeutics and enlists all their major and minor projects
  • The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Autism
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Autism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Autism Overview
Therapeutics Development
Pipeline Products for Autism - Overview
Pipeline Products for Autism - Comparative Analysis
Autism - Therapeutics under Development by Companies
Autism - Therapeutics under Investigation by Universities/Institutes
Autism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Autism - Products under Development by Companies
Autism - Products under Investigation by Universities/Institutes
Autism - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc.
AgeneBio Inc.
APeT Holding BV
BioCrea GmbH
BrainStorm Cell Therapeutics Inc.
Cellceutix Corporation
Confluence Pharmaceuticals LLC
Coronis Partners Ltd.
Curemark, LLC
F. Hoffmann-La Roche Ltd.
GW Pharmaceuticals Plc
Heptares Therapeutics Limited
Intra-Cellular Therapies, Inc.
MedDay SA
Omeros Corporation
Otsuka Holdings Co., Ltd.
Retrophin Inc.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Autism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan + quinidine sulfate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acamprosate calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbetocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-0306 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-AT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
histamine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-14242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-391 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-1103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niacinamide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NurOwn - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7314 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-999 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block Chloride Channels for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target GPR63 for Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Autism and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Featured News & Press Releases
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism
May 31, 2012: Study Reports New Treatment For Irritability In Autism
Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
Dec 16, 2010: Otsuka Announces Defendants Appeal From Final Judgment In US Abilify Patent Litigation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Autism, H2 2016
Number of Products under Development for Autism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Autism - Pipeline by Addex Therapeutics Ltd, H2 2016
Autism - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
Autism - Pipeline by AgeneBio Inc., H2 2016
Autism - Pipeline by APeT Holding BV, H2 2016
Autism - Pipeline by BioCrea GmbH, H2 2016
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016
Autism - Pipeline by Cellceutix Corporation, H2 2016
Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
Autism - Pipeline by Coronis Partners Ltd., H2 2016
Autism - Pipeline by Curemark, LLC, H2 2016
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Autism - Pipeline by GW Pharmaceuticals Plc, H2 2016
Autism - Pipeline by Heptares Therapeutics Limited, H2 2016
Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Autism - Pipeline by MedDay SA, H2 2016
Autism - Pipeline by Omeros Corporation, H2 2016
Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
Autism - Pipeline by Retrophin Inc., H2 2016
Autism - Pipeline by Saniona AB, H2 2016
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Autism - Dormant Projects, H2 2016
Autism - Dormant Projects (Contd..1), H2 2016
Autism - Dormant Projects (Contd..2), H2 2016
Autism - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Autism, H2 2016
Number of Products under Development for Autism - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc.
AgeneBio Inc.
APeT Holding BV
BioCrea GmbH
BrainStorm Cell Therapeutics Inc.
Cellceutix Corporation
Confluence Pharmaceuticals LLC
Coronis Partners Ltd.
Curemark, LLC
F. Hoffmann-La Roche Ltd.
GW Pharmaceuticals Plc
Heptares Therapeutics Limited
Intra-Cellular Therapies, Inc.
MedDay SA
Omeros Corporation
Otsuka Holdings Co., Ltd.
Retrophin Inc.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Skip to top


Omeros Corporation - Product Pipeline Review - 2016 US$ 1,500.00 Aug, 2016 · 115 pages
BioCrea GmbH - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 24 pages
Saniona AB - Product Pipeline Review - 2016 US$ 1,500.00 Aug, 2016 · 55 pages
Anal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 86 pages

Ask Your Question

Autism - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: